Flavonoid-Polymer Nanocomplexes for Anti-Angiogenic Eye Therapy

The patent uses flavonoid-polymer conjugates as intermediary carriers to deliver anti-VEGF drugs. The conjugates act as mediators between the drug and the target tissue, enabling controlled release and reducing direct tissue damage. The flavonoid-polymer conjugate system serves as a protective intermediary that maintains drug efficacy while minimizing harmful side effects at the injection site and within the eye.

The patent modifies the physical and chemical parameters of the drug delivery system by creating self-assembled nanocomplexes with specific size, charge, and surface properties. The nanocomplexes have controlled hydrodynamic diameter, zeta potential, and surface hydrophobicity to optimize their interaction with ocular tissues. These parameter changes enable the drug system to achieve therapeutic efficacy while reducing toxicity through optimized physical characteristics.

The patent implements sustained-release drug delivery systems using flavonoid-polymer conjugates that continuously release anti-VEGF drug over extended periods. The conjugates maintain therapeutic drug levels in the eye for months, providing continuous disease control without requiring frequent injections. This continuity of useful action reduces the frequency of medical interventions while maintaining treatment efficacy.

The patent employs preliminary formulation of drugs into flavonoid-polymer conjugates with controlled release characteristics. The conjugates are pre-designed to release drug in a controlled manner over time, anticipating the need for sustained therapy. This preliminary action of creating sustained-release formulations allows for reduced injection frequency and long-term disease control without requiring continuous frequent interventions.

The patent uses flavonoid-polymer conjugates as intermediary carriers that facilitate drug delivery through alternative, less invasive routes. The conjugates act as mediators that can transport anti-VEGF drugs through the blood-ocular barrier or via topical application, avoiding the need for direct intravitreal needle insertion. This intermediary system maintains treatment efficacy while eliminating the invasive route and its associated tissue damage and infection risks.

The patent replaces the mechanical intravitreal injection system with alternative delivery mechanisms based on the flavonoid-polymer conjugate system. Instead of using mechanical needles and syringes to inject drugs directly into the vitreous, the system uses molecular-level interactions and controlled release mechanisms. This substitution of mechanical delivery with biochemical delivery systems eliminates physical trauma and infection risk while maintaining therapeutic efficacy.

The patent employs flavonoid-polymer conjugates as intermediary carriers that enhance drug transport to the retina. The conjugates act as mediators that facilitate blood-brain barrier penetration and ocular tissue accumulation. They improve the bioavailability of anti-VEGF drugs by enabling their passage through protective barriers and enhancing their accumulation in the target retina, thereby increasing anti-angiogenic activity without requiring higher drug doses.

The patent creates composite nanocomplex systems combining flavonoid-polymer conjugates with anti-VEGF drugs. This composite material approach leverages the beneficial properties of both components: the flavonoid-polymer conjugate provides enhanced bioavailability and tissue accumulation, while the anti-VEGF drug delivers therapeutic anti-angiogenic activity. The composite structure synergistically improves both drug delivery and therapeutic efficacy, achieving superior anti-angiogenic activity with optimized drug accumulation in the retina.